Annemarie G. Hirsch

Dr. Annemarie G. Hirsch

Department of Population Health Sciences, Geisinger, Danville, PA 17822, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2016 in Allergy
Verified
Journal Article
Closed access
PDF file
Annemarie G. HirschAnnemarie G. Hirsch
Annemarie G. Hirsch
WSW. F. Stewart
W. F. Stewart
ASA. S. Sundaresan
A. S. Sundaresan
AYA. J. Young
A. J. Young
TKT. L. Kennedy
T. L. Kennedy
BSB. S. Schwartz
B. S. Schwartz

26 August 2016 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
PDF file
Annemarie G. HirschAnnemarie G. Hirsch
Annemarie G. Hirsch
JPJ. Pollak
J. Pollak
TGT. A. Glass
T. A. Glass
MPM. N. Poulsen
M. N. Poulsen
LBL. Bailey‐Davis
L. Bailey‐Davis
BSB. S. Schwartz
B. S. Schwartz

31 July 2017 in Diabetes Care
Verified
Journal Article
Open access
PDF file
MLMichelle R. Lent
Michelle R. Lent
PBPeter N. Benotti
Peter N. Benotti
TMTooraj Mirshahi
Tooraj Mirshahi
GGGlenn S. Gerhard
Glenn S. Gerhard
WSWilliam E. Strodel
William E. Strodel
GWG. Craig Wood
G. Craig Wood
OBJECTIVE: This study assessed all-cause and specific-cause mortality after Roux-en-Y gastric bypass (RYGB) and in matched control subjects, stratified by diabetes status. RESEARCH DESIGN AND METHODS: RYGB patients were matched by age, BMI, sex, and diabetes status at time of surgery to nonsurgical control subjects using data from the electronic health record. Kaplan-Meier curves and Cox regression were used to assess differences in all-cause and specific-cause mortality between RYGB patients and control subjects with and without diabetes. RESULTS: Of the 3,242 eligible RYGB patients enrolled from January 2004 to December 2015, control subjects were identified for 2,428 (n = 625 with diabetes and n = 1,803 without diabetes). Median postoperative follow-up was 5.8 years for patients with diabetes and 6.7 years for patients without diabetes. All-cause mortality was reduced in RYGB patients compared with control subjects only for those with diabetes at the time of surgery (adjusted hazard ratio 0.44; P < 0.0001). Mortality was not significantly improved in RYGB patients without diabetes compared with control subjects without diabetes (adjusted hazard ratio 0.84; P = 0.37). Deaths from cardiovascular diseases (P = 0.011), respiratory conditions (P = 0.017), and diabetes P = 0.011) were more frequent in control subjects with diabetes than in RYGB patients with diabetes. RYGB patients without diabetes were less likely to die of cancer (P = 0.0038) and respiratory diseases (P = 0.046) than control subjects without diabetes but were at higher risk of death from external causes (P = 0.012), including intentional self-harm (P = 0.025), than control subjects without diabetes. CONCLUSIONS: All-cause mortality benefits of RYGB are driven predominantly by patients with diabetes at the time of surgery. RYGB patients with diabetes were less likely to die of cardiovascular diseases, diabetes, and respiratory conditions than their counterparts without RYGB.

11 November 2019 in Allergy
Verified
Journal Article
Closed access
PDF file
Annemarie G. HirschAnnemarie G. Hirsch
Annemarie G. Hirsch
CNCara Nordberg
Cara Nordberg
KBKaren Bandeen‐Roche
Karen Bandeen‐Roche
BTBruce K. Tan
Bruce K. Tan
RSRobert P. Schleimer
Robert P. Schleimer
BSBrian Schwartz
Brian Schwartz

31 August 2015 in Allergy
Verified
Journal Article
Closed access
PDF file
Annemarie G. HirschAnnemarie G. Hirsch
Annemarie G. Hirsch
XYX. S. Yan
X. S. Yan
ASA. S. Sundaresan
A. S. Sundaresan
BTB. K. Tan
B. K. Tan
RSR. P. Schleimer
R. P. Schleimer
BSB. S. Schwartz
B. S. Schwartz

26 November 2020 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
Annemarie G. HirschAnnemarie G. Hirsch
Annemarie G. Hirsch
MPMelissa N. Poulsen
Melissa N. Poulsen
CNCara Nordberg
Cara Nordberg
KMKatherine A. Moon
Katherine A. Moon
ARAlison W. Rebman
Alison W. Rebman
BSBrian S. Schwartz
Brian S. Schwartz
Background: Longer time between symptom onset and treatment of Lyme disease has been associated with poor outcomes. Reducing time-to-treatment requires knowledge of risks for treatment delays. We conducted a population-based study to evaluate factors associated with delayed treatment of Lyme disease and the relation between delayed treatment and post-treatment Lyme disease syndrome (PTLDS).Methods: We mailed questionnaires to 5,314 individuals with a Lyme disease diagnosis or blood test followed by an antibiotic order in the medical record of a Pennsylvania health system from 2015 to 2017. Analyses were confined to 778 respondents who reported that they were treated for Lyme disease within the past 5 years and reported a rash and/or a positive blood test for Lyme disease. Time-to-treatment was calculated as the sum of two windows before and after seeking care for Lyme disease symptoms: time to first medical contact and time under care. We used logistic regression to evaluate factors associated with delayed time-to-treatment in each time window (>14 days vs. ≤14 days) and the association between total time-to-treatment (>30 days vs. ≤30 days) and PTLDS. We used inverse probability weighting to calculate estimates for the study's source population (5,314 individuals sent questionnaires).Results: In the source population, 25% had time to first contact >14 days, 21% had time under care >14 days, and 31% had a total time-to-treatment >30 days. Being uninsured and attributing initial symptoms to something other than Lyme disease were positively associated with delayed time to first medical contact, while seeking care at an urgent care or emergency setting (vs. primary care) was negatively associated. Diagnoses between November and April, and the absence of rash were positively associated with delays. Individuals whose treatment was delayed, defined as time-to treatment >30 days had 2.26 (95% confidence interval: 1.25, 4.05) times the odds of PTLDS as those who were treated within 30 days of symptom onset.Conclusions: In a population-based study in Pennsylvania, one-third of Lyme disease patients reported delayed treatment, which was associated with PTLDS. To improve Lyme disease outcomes, prevention efforts should aim to reduce the time before and after seeking care.